News
Yuhan to license out a gastrointestinal drug candidate to Processa for $415 million
Yuhan Corporation entered into a licensing agreement worth up to $415 million with Processa Pharmaceuticals for the development of YH12852, a small molecule drug in
[Job Opening] Business Development Manager – San Diego office
Yuhan USA Corporation was established in January 2018 as a wholly-owned subsidiary of Yuhan Corporation, Korea’s largest pharmaceutical company with a 94-year heritage. As an
Yuhan-AbClon now in the race for a COVID-19 therapeutic antibody
Yuhan and AbClon have joined the list of pharmaceutical companies that are in the race to develop a therapeutic antibody for COVID-19. They have identified
Yuhan expands its allergy treatment pipeline with the in-license of GI-301 from GI Innovation
Yuhan Corporation has in-licensed GI Innovation’s allergy treatment pipeline (GI-301) from GI Innovation in a deal that could potentially total $1.2 billion. Yuhan and GI
Yuhan Corporation to recoup KRW 200 billion investment in five years
Yuhan Corporation’s global R&D and open innovation strategy – in which they introduce early assets from the startups, conduct preclinical & early clinical studies, then
J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation
Here’s an update from our business partner Janssen Biotech that JNJ-6372 in combination with Lazertinib (YH25448), a novel third-generation EGFR TKI for advanced NSCLC that